Investing.com -- Maze Therapeutics, a clinical-stage biopharmaceutical company, launched its initial public offering (IPO) today, with shares starting to trade at $16.12. The company priced 8,750,000 ...

(Reuters) -Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 billion. Shares of the ...

Metsera, along with Maze Therapeutics, gave U.S. health care first-time share sales its best month since October.

Underwriters have a 30-day option to buy an additional 1.8 million shares. Beta Bionics also agreed to sell 1 million shares in a private placement to an existing investor at $17 per share. Beta ...

DailyPay, a financial services firm that helps workers access their pay early, has kicked off preparations for a potential U.S. stock market listing that could come as soon as the second half of the ...

Saudi Arabia is experiencing a boom in IPO activity, signaling the liberalization of its economy and a shift away from government-led privatizations that once dominated its investment market. The ...

The future of Portugal's Novo Banco is taking a clearer shape as US private equity firm Lone Star signals its intention to pursue an initial public offering (IPO) for a stake of up to 30% in the ...

GB Logistics share price had a weak debut on BSE SME, opening at ₹81.60, 20% lower than the IPO price of ₹102. The IPO was ...

H.M. Electro Mech shares made a decent debut on Friday, January 31, listing at ₹81 on BSE SME, a premium of 8 percent over ...

Infinity Natural Resources Inc. priced its initial public offering above the midpoint of its range in a sign of a strong ...

U.S. private equity firm Lone Star has told the Portuguese government that it is likely to sell a 25-30% stake in Novo Banco ...

The UK biotech sector raised £3.5 billion in equity financing last year amid challenges, according to a BIA report.